Tucson, AZNCT07288138Now EnrollingIRB Ready

Metabolic Dysfunction-associated Steatohepatitis Clinical Trial in Tucson, AZ

Access cutting-edge metabolic dysfunction-associated steatohepatitis treatment through this clinical trial at a research site in Tucson. Study-provided care at no cost to qualified participants.

Sponsored by Eccogene

Quick Self-Assessment

See if you qualify for this Tucson location

Preparing your pre-screening questions…

Expert Care in Tucson

Access metabolic dysfunction-associated steatohepatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metabolic dysfunction-associated steatohepatitis treatment provided free

Apply for This Tucson Location

Check if you qualify for this metabolic dysfunction-associated steatohepatitis clinical trial in Tucson, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tucson

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tucson site if eligible
  4. 4Begin participation

About This Metabolic Dysfunction-associated Steatohepatitis Study in Tucson

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

Sponsor: Eccogene

Who Can Participate

Inclusion Criteria

Adults between 18 and 75 years of age, inclusive, who can provide written informed consent and comply with study procedures.
Diagnosis of presumed MASH based on: liver biopsy within 180 days prior to screening showing an NAFLD activity score (NAS) of ≥3 and a fibrosis score (F) of F1-3 OR FibroScan® CAP \>280 dB/m at screening with presence of metabolic risk factors.
Evidence of hepatic steatosis confirmed by FibroScan® LSM \> 7 kPa and \< 20 kPa and MRI-PDFF \>8% at screening.
BMI \>25 kg/m\^2 to \<50 kg/m\^2 (non-Asian); BMI ≥23.0 to \<50.0 kg/m\^2 (Asian).
ALT ≥60 U/L at the first screening visit and stability of ALT and AST levels during the screening period.
Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m\^2 (Chronic Kidney Disease Epidemiology Collaboration, \[CKD-EPI\]).
Stable body weight (no \>5% change) for at least 6 months prior to screening.
Willing to comply with contraception requirements (as applicable to males and females of childbearing potential).
In the opinion of the investigator, able to participate safely and complete required MRI/biomarker assessments.

Exclusion Criteria

Chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH, including alcoholic liver disease, autoimmune hepatitis, cholestatic disease, genetic liver diseases, or drug-induced liver injury.
Presence of cirrhosis on liver histology according to the assessment of the central reader, and/or cross-sectional imaging evidence consistent with cirrhosis and/or portal hypertension (e.g, nodular liver contour; portosystemic collaterals, ascites, splenomegaly; known presence or history of esophageal varices; and/or elastography evidence consistent with cirrhosis).
ALT and/or AST \>5× Upper Limit of Normal (ULN) or ALP \>2×ULN at screening.
Clinically significant thyroid or adrenal dysfunction, including uncontrolled hypothyroidism, hyperthyroidism, or adrenal disorders.
Type 1 diabetes, HbA1c \>9.5%, or unstable type 2 diabetes requiring medication changes within 90 days.
Use of medications that affect liver fat or fibrosis (e.g., Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) not on a stable dose, pioglitazone, obeticholic acid, high-dose vitamin E, hepatotoxic drugs) within protocol-specified washout periods.
Significant alcohol use within 1 year prior to screening.
Recent cardiovascular events, including myocardial infraction (MI), stroke, unstable angina, heart failure (New York heart association \[NYHA III-IV\]), or uncontrolled arrhythmia.
Current or recent serious psychiatric illness, including psychosis, active suicidal ideation, or suicide attempt within 5 years.
Pregnancy, breastfeeding, or conditions that increase risk or interfere with study procedures, including MRI contraindications or other investigator-determined safety concerns.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT07288138) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metabolic Dysfunction-associated Steatohepatitis Treatment Options in Tucson, AZ

If you're searching for metabolic dysfunction-associated steatohepatitis treatment options in Tucson, AZ, this clinical trial (NCT07288138) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metabolic dysfunction-associated steatohepatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metabolic dysfunction-associated steatohepatitis clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Tucson, AZ

See all essential tremor clinical trials recruiting in Tucson — not just this study.

Browse Essential Tremor Trials in Tucson →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsNASH TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Tucson?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tucson, AZ